Y(90) -Ibritumomab tiuxetan (Y(90) -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05). (Q40525462)

From Wikidata

Jump to navigation Jump to search

scientific article published on 28 September 2016

Language	Label	Description	Also known as
English	Y(90) -Ibritumomab tiuxetan (Y(90) -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05).	scientific article published on 28 September 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Y(90) -Ibritumomab tiuxetan (Y(90) -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05). (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

author name string

Michèle Voegeli

1

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Stephanie Rondeau

2

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Simona Berardi Vilei

3

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Erika Lerch

4

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Luciano Wannesson

5

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Thomas Pabst

6

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Jochen Rentschler

7

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Mario Bargetzi

8

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Lorenz Jost

9

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Nicolas Ketterer

10

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Angelika Bischof Delaloye

11

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Michele Ghielmini

12

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

publication date

28 September 2016

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Hematological Oncology

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FHON.2348

21 January 2018

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FHON.2348

21 January 2018

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FHON.2348

21 January 2018

Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FHON.2348

21 January 2018

Efficient mobilization of PBSC with vinorelbine/G-CSF in patients with malignant lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FHON.2348

21 January 2018

Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FHON.2348

21 January 2018

Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FHON.2348

21 January 2018

Matched-cohort analysis of autologous hematopoietic cell transplantation with radioimmunotherapy versus total body irradiation-based conditioning for poor-risk diffuse large cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FHON.2348

21 January 2018

Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the

1 reference

https://api.crossref.org/works/10.1002%2FHON.2348

21 January 2018

Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.

1 reference

https://api.crossref.org/works/10.1002%2FHON.2348

21 January 2018

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FHON.2348

21 January 2018

High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FHON.2348

21 January 2018

High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas.

1 reference

https://api.crossref.org/works/10.1002%2FHON.2348

21 January 2018

High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FHON.2348

21 January 2018

Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM.

1 reference

https://api.crossref.org/works/10.1002%2FHON.2348

21 January 2018

Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FHON.2348

21 January 2018

90Y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell transplantation in aggressive non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FHON.2348

21 January 2018

High-dose therapy and autologous stem-cell transplantation can improve event-free survival for indolent lymphoma: a study using patients as their own controls

1 reference

https://api.crossref.org/works/10.1002%2FHON.2348

7 January 2021

based on heuristic

inferred from DOI database lookup

Single-agent high-dose melphalan salvage therapy for Hodgkin's disease: cost, safety, and long-term efficacy

1 reference

https://api.crossref.org/works/10.1002%2FHON.2348

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HON.2348

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40525462&oldid=1496236488"